0001384101-20-000039.txt : 20200304
0001384101-20-000039.hdr.sgml : 20200304
20200304174907
ACCESSION NUMBER: 0001384101-20-000039
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200303
FILED AS OF DATE: 20200304
DATE AS OF CHANGE: 20200304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kennedy Giulia C
CENTRAL INDEX KEY: 0001769333
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36156
FILM NUMBER: 20688584
MAIL ADDRESS:
STREET 1: 338 MAIN STREET #26E
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94105
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERACYTE, INC.
CENTRAL INDEX KEY: 0001384101
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 205455398
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 243-6300
MAIL ADDRESS:
STREET 1: 6000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: CALDEROME INC
DATE OF NAME CHANGE: 20061219
4
1
wf-form4_158336213084937.xml
FORM 4
X0306
4
2020-03-03
0
0001384101
VERACYTE, INC.
VCYT
0001769333
Kennedy Giulia C
6000 SHORELINE COURT
SUITE 300
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Scientific & Med Officer
Common Stock
2020-03-03
4
M
0
3750
6.45
A
102872
D
Common Stock
2020-03-03
4
M
0
1563
5.43
A
104435
D
Common Stock
2020-03-03
4
M
0
5313
9.05
A
109748
D
Common Stock
2020-03-03
4
M
0
4407
5.98
A
114155
D
Common Stock
2020-03-03
4
S
0
30542
25.3489
D
83613
D
Common Stock
2020-03-03
4
S
0
2339
25.9051
D
81274
D
Stock Option (right to buy)
6.45
2020-03-03
4
M
0
3750
6.45
D
2026-02-28
Common Stock
3750.0
2
D
Stock Option (right to buy)
5.43
2020-03-03
4
M
0
1563
5.43
D
2026-03-14
Common Stock
1563.0
522
D
Stock Option (right to buy)
9.05
2020-03-03
4
M
0
5313
9.05
D
2027-03-02
Common Stock
5313.0
21250
D
Stock Option (right to buy)
5.98
2020-03-03
4
M
0
4407
5.98
D
2028-03-01
Common Stock
4407.0
35250
D
The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019.
Represents weighted average sales price. Sale prices for the transactions range from $24.77 to $25.75. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Represents weighted average sales price. Sale prices for the transactions range from $25.78 to $26.05. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
The option is fully vested.
The option became exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
/s/ Keith Kennedy as attorney-in-fact
2020-03-04